GlycoMimetics ROA 2012-2025 | CBIO
Current and historical return on assets (ROA) values for GlycoMimetics (CBIO) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| GlycoMimetics ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2025-03-31 |
$-0.03B |
$0.01B |
-203.51% |
| 2024-12-31 |
$-0.04B |
$0.01B |
-178.82% |
| 2024-09-30 |
$-0.04B |
$0.02B |
-134.45% |
| 2024-06-30 |
$-0.04B |
$0.02B |
-100.00% |
| 2024-03-31 |
$-0.04B |
$0.03B |
-76.29% |
| 2023-12-31 |
$-0.04B |
$0.05B |
-62.88% |
| 2023-09-30 |
$-0.04B |
$0.05B |
-62.71% |
| 2023-06-30 |
$-0.04B |
$0.06B |
-61.92% |
| 2023-03-31 |
$-0.04B |
$0.07B |
-69.42% |
| 2022-12-31 |
$-0.05B |
$0.05B |
-74.02% |
| 2022-09-30 |
$-0.05B |
$0.06B |
-72.97% |
| 2022-06-30 |
$-0.06B |
$0.07B |
-71.26% |
| 2022-03-31 |
$-0.06B |
$0.08B |
-61.92% |
| 2021-12-31 |
$-0.06B |
$0.09B |
-53.45% |
| 2021-09-30 |
$-0.06B |
$0.11B |
-47.56% |
| 2021-06-30 |
$-0.06B |
$0.12B |
-41.80% |
| 2021-03-31 |
$-0.06B |
$0.14B |
-39.39% |
| 2020-12-31 |
$-0.05B |
$0.14B |
-33.93% |
| 2020-09-30 |
$-0.05B |
$0.15B |
-31.97% |
| 2020-06-30 |
$-0.05B |
$0.16B |
-29.94% |
| 2020-03-31 |
$-0.05B |
$0.16B |
-29.63% |
| 2019-12-31 |
$-0.06B |
$0.17B |
-31.18% |
| 2019-09-30 |
$-0.06B |
$0.18B |
-28.82% |
| 2019-06-30 |
$-0.06B |
$0.19B |
-26.79% |
| 2019-03-31 |
$-0.05B |
$0.20B |
-23.18% |
| 2018-12-31 |
$-0.05B |
$0.22B |
-21.24% |
| 2018-09-30 |
$-0.04B |
$0.23B |
-21.03% |
| 2018-06-30 |
$-0.04B |
$0.24B |
-21.98% |
| 2018-03-31 |
$-0.04B |
$0.25B |
-24.10% |
| 2017-12-31 |
$-0.03B |
$0.13B |
-32.67% |
| 2017-09-30 |
$-0.03B |
$0.12B |
-40.38% |
| 2017-06-30 |
$-0.03B |
$0.12B |
-51.41% |
| 2017-03-31 |
$-0.03B |
$0.04B |
-69.95% |
| 2016-12-31 |
$-0.03B |
$0.04B |
-68.45% |
| 2016-09-30 |
$-0.03B |
$0.05B |
-68.39% |
| 2016-06-30 |
$-0.03B |
$0.06B |
-63.68% |
| 2016-03-31 |
$-0.01B |
$0.04B |
-27.05% |
| 2015-12-31 |
$-0.01B |
$0.05B |
-24.30% |
| 2015-09-30 |
$-0.01B |
$0.06B |
-19.73% |
| 2015-06-30 |
$-0.01B |
$0.06B |
-19.21% |
| 2015-03-31 |
$-0.01B |
$0.05B |
-22.13% |
| 2014-12-31 |
$-0.01B |
$0.06B |
-17.96% |
| 2014-09-30 |
$-0.01B |
$0.06B |
-16.58% |
| 2014-06-30 |
$-0.01B |
$0.07B |
-14.18% |
| 2014-03-31 |
$-0.02B |
$0.06B |
-87.67% |
| 2013-12-31 |
$-0.01B |
$0.01B |
-293.33% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
